Treatment with low dose IL-2 to boost regulatory T cells in recent onset T1D resulted in expected expansion of regulatory T cells in treated subjects but the trial was terminated early due to unexpected rapid loss of C-peptide that implied potential acceleration of disease (97). The gene discussed is IL2; the disease is type 1 diabetes mellitus.